Summary
Only one multicentric (16 centers)
randomized-controlled-trial (RCT) from Japan was found to be eligible for
inclusion in this review. This was a three-arm trial comparing acetyl
salicylic acid (ASA) alone with intravenous immunoglobulins (IVIG) and ASA
treatment, and with IVIG alone; only last two arms (including 102
children) were included for this review. The dose of IVIG was 200mg/kg
daily for five days, and of ASA was 30 to 50mg/kg/day in three divided
doses until the fever had subsided, then 10 to 30 mg/kg/day once a day
until "the acute reaction had also disappeared." Children were enrolled if
they presented within seven days of onset of symptoms, and two dimensional
echocardiography was performed three times a week until 60 days after the
onset of symptoms. Any abnormalities on echocardiography were followed by
selective coronary angiography. No significant difference was found in the
incidence of coronary artery lesions up to 30 days from onset of symptoms
(RR 0.97; 95% CI 0.43 to 2.19) or prevalence after 30 days post onset of
symptoms (RR 1.30; 95% CI 0.37 to 4.56). The authors concluded that there
is insufficient evidence to indicate whether children with KD should or
should not continue to receive salicylate as part of their treatment
regimen.
Commentary
Are the results valid?
The clinical question raised by this systematic review
is relevant. The search strategy was primarily designed to study the
outcome of coronary artery lesions. For this updated version, only
specialized registers and central registers of the Cochrane group were
searched for, and no additional studies were found. In the only included
study, randomization method was uncertain and blinding was not done. The
outcome assessed is functionally important but it would have been helpful
if the other important outcomes such as duration and intensity of fever,
patient comfort, and duration of hospitalization were also included. The
sample size is also less for studying the outcome of coronary lesions
because of their relative rarity in IVIG treated patients.
How precise and clinically significant is the treatment
effect?
Although the included study reported no benefit in
terms of incidence of new coronary artery lesions up to day 30 and their
prevalence after day 30, the confidence intervals were wide thus not
ruling out possibility of benefit or even harm. The other outcomes such as
duration and intensity of fever were not reported in this review. Any
adverse effects of salicylates, the primary concern for their usage, were
also not reported in this review.
Implications for Practice and Policy
IVIG has become a standard treatment modality for
children with KD because of their proven role in reducing the coronary
complications(1). It appears that salicylates have no additional advantage
of further reduction in these complications. However, these results are
valid only for patients who are also receiving simultaneous IVIG therapy
and can not be extrapolated for those not receiving IVIG because of any
reason. Also, the results of the review are based on relatively small
number of patients.
In the absence of a clear cut evidence of benefit or
harm with salicylates, it appears unlikely that the current practice of
using salicylates as well as IVIG would change on the basis of these
results. Moreover, some other studies (not included in this review because
of methodological concerns or not meeting inclusion criteria) have
reported the advantage of salicylates in reducing the duration of
fever(2,3). Good quality and adequately powered multicentric RCTs would be
required to provide a clear cut recommendation on this issue. Also, the
other patient oriented outcomes such as fever clearance time and cost
issues need to be studied in future trials.
1. Oates-Whitehead RM, Baumer JH, Haines L, Love S,
Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the
treatment of Kawasaki disease in children. Cochrane Database Syst Rev
2003; 4: CD004000.
2. Akagi T, Kato H, Inoue O, Sato N. Salicylate
treatment in Kawasaki disease: high dose or low dose? Eur J Pediatr
1991; 150: 642-646.
3. Melish ME, Takahashi M, Shulman ST, Reddy DV, Mason
WH, Elise Duffy C, et al. Comparison of low dose aspirin (LDA) vs.
high dose aspirin (HDA) as an adjunct to intravenous gamma globulin (IVIG)
in the treatment of Kawasaki disease. Pediatr Res 1992; 31:170A.